Congress funds AI push to speed pediatric cancer cures—with privacy guardrails

What it does

This bill creates a federal coordinator position to oversee efforts using artificial intelligence to improve diagnosis, treatment, and prevention of pediatric cancer. The coordinator will work with the Department of Health and Human Services to integrate AI tools into the existing Childhood Cancer Data Initiative, improve how patient data is shared across health systems while protecting privacy, and establish standards for AI-ready data. The bill authorizes $100 million annually from 2027–2031 for these efforts.

Why we flagged it

The bill's core function is establishing a federal coordinator and funding mechanism to integrate AI into childhood cancer research and treatment. It is a public-health research initiative, not a regulatory carve-out or industry subsidy.

What the text implies

• The bill's success depends on voluntary participation by private health systems and academic institutions in data-sharing arrangements; without enforcement mechanisms or incentives, adoption may be uneven.
• Interoperability standards for AI-ready patient data may create new compliance costs for smaller hospitals and clinics, potentially widening disparities in access to AI-driven pediatric cancer care.
• The 180-day reporting requirement is narrow; no ongoing transparency mechanism is mandated for how the Coordinator allocates funds or measures outcomes.

Who it affects

The bill funds research infrastructure and coordination to accelerate pediatric cancer treatment using AI, with explicit privacy protections and patient control over health data. Ordinary citizens—particularly families with children facing cancer—benefit from faster innovation and better clinical trial access, while the privacy and interoperability safeguards protect broader public interests in health data governance.

Who stands to gain

• healthcare technology vendors (EHR/data platform providers)
• AI/machine learning software companies
• academic medical centers and research institutions
• pharmaceutical and biotech companies developing pediatric cancer treatments

Named in the bill

Department of Health and Human Services (HHS), Childhood Cancer Data Initiative (CCDI), Domestic Policy Council, House Committee on Energy and Commerce, House Committee on Science, Space, and Technology, Senate Committee on Health, Education, Labor, and Pensions, Senate Committee on Commerce, Science, and Transportation, National Artificial Intelligence Initiative of 2020

Where it stands

2 cosponsors: 1 Democrats, 1 Republicans.

• Jul 9, 2026 — Introduced · Congress.gov: “Introduced in House”
• Jul 9, 2026 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

1 lobbying clients named this bill on 1 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $590,000 in lobbying spend. A filing names 40 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 0% of bills with at least one filing.

Michael McCaul, the sponsor, reported $80,800 in PAC receipts in the 2026 cycle.

• Blood Cancer United (fka the Leukemia & Lymphoma Society) — $590,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.